Back

Ventricular substrate characteristics using omnipolar technology-derived vector disarray and peak frequency

30 March 2025 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Poster session 2: arrhythmia mechanisms, device therapy, and ventricular arrhythmias Ablation of Ventricular Arrhythmias EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Federica Giordano

Hospital Santa Maria della Misericordia, Udine (Italy)

146 More presentations in this session

Presentation thumbnail
Impact of ICD and CRT-D implantation on survival in ischemic and non-ischemic cardiomyopathy: a single-center croatian retrospective cohort study and comparative insights with the DANISH trial
Assistant Professor M. Puljevic (Zagreb, HR)
Abstract
Presentation thumbnail
Do the longer leadless pacemakers with helix screws affect tricuspid regurgitation after pacemaker implantation?
Presentation thumbnail
Classification of atrial fibrillation burden pattern in cardiac implantable electronic devices
Mr S. Majumder (Minneapolis, US)
Abstract Slides Video
Presentation thumbnail
Life-threatening arrhythmia in patients with suspected acute myocarditis
Miss K. Bulatova (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Early outcomes of left bundle branch area pacing upgrade in pediatric pacing-induced cardiomyopathy
Mr Y. Turubayev (Astana, KZ)
Abstract Slides Video

Access the full session

Session thumbnail
Poster session 2: arrhythmia mechanisms, device therapy, and ventricular arrhythmias

The Event

Event poster

EHRA 2025

30 March - 1 April 2025
You may be interested in
thumbnail
Congress Presentation
Ablation is alternative to ICD therapy in post-myocardial infarction patients with haemodynamically well-tolerated sustained monomorphic VT and LVEF>40%: con
thumbnail
Congress Presentation
Case 1 - first choice treatment: antiarrhythmic drugs or catheter ablation?
thumbnail
Congress Presentation
Case 2 - implantable cardioverter defibrillator, catheter ablation, or both for secondary prevention?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources